Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
A Phase 2, Double-blind, Placebo-controlled, Randomized, International, Multicenter Study of Oral TAC 101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Sponsor: Quintiles, Inc.
Listed as NCT00687596, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Quintiles, Inc., it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Feb 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Quintiles, Inc.
- Taiho Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .